Drug intelligence / Profile preview

Zinituss

Development stage
Unknown
Lead developer
Zinnia Life Sciences
Modality
Small Molecules
Administration
Oral
01

Overview

Zinituss is an oral combination syrup developed by Zinnia Life Sciences for the temporary relief of symptoms associated with the common cold, flu, allergies, and upper respiratory tract infections. It is formulated with three active ingredients: dextromethorphan (a cough suppressant), cetirizine (a second-generation antihistamine), and phenylephrine (a nasal decongestant). Dextromethorphan acts on the cough center in the brain to suppress dry, non-productive coughs. Cetirizine selectively inhibits peripheral histamine H1 receptors to alleviate allergy symptoms such as sneezing, runny nose, and watery eyes. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the nasal passages, thereby reducing swelling and congestion.

Brand names
Zinituss
Other names
cetirizine + dextromethorphan + phenylephrinecetirizine + dextromethorphan + phenylephrine syrupcetirizine dihydrochloride + dextromethorphan hydrobromide + phenylephrine hydrochloride
02

Targets

ADRA1A (α1A)NMDAR (Glutamate receptor ionotropic, NMDA)HRH1 (Histamine H1 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on Zinituss.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinituss.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call